Skip to main content

Table 1 Cytotoxicity of Guieranone A and Doxorubicin in various cancer cell lines

From: Cytotoxicity, anti-angiogenic, apoptotic effects and transcript profiling of a naturally occurring naphthyl butenone, guieranone A

Cell lines Sample and IC 50values
Guieranone A   Doxorubicin  
   
μg/ml μM μg/ml μM
CCRF-CEM 0.73 ± 0.11 2.31 ± 0.35 0.62 ± 0.003 1.14 ± 0.005
CEM/ADR5000 1.01 ± 0.09 (1.38) 3.19 ± 0.28 >20 (>32.26) >36.8
MiaPaCa-2 3.91 ± 0.25 12.37 ± 0.79 0.95 ± 0.06 1.75 ± 0.11
Capan-1 9.19 ± 2.29 29.08 ± 7.24 4.06 ± 1.18 7.47 ± 2.17
MCF-7 1.08 ± 0.32 3.42 ± 0.90 0.59 ± 0.05 1.08 ± 0.09
SW-680 >20 >63.29 0.93 ± 0.09 1.71 ± 0.17
786-0 3.68 ± 0.54 11.32 ± 1.70 0.60 ± 0.09 1.10 ± 0.17
U87MG 2.46 ± 0.02 7.78 ± 0.05 0.37 ± 0.08 0.68 ± 0.14
A549 0.72 ± 0.07 2.28 ± 0.22 1.69 ± 0.05 3.11 ± 0.09
Colo-38 2.43 ± 0.75 7.69 ± 1.38 0.81 ± 0.06 1.49 ± 0.11
HeLa 0.51 ± 0.04 1.61 ± 0.13 0.26 ± 0.02 0.48 ± 0.04
Caski 1.18 ± 0.11 3.73 ± 0.35 0.58 ± 0.02 1.07 ± 0.04
AML12 (EC50)* >20 >63.29 >20 >36.8
  1. ac*EC50: effective dose showing 50% inhibition of growth proliferation.